Susquehanna International Group, LLP Annovis Bio, Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2025
A detailed history of Susquehanna International Group, LLP transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 127,705 shares of ANVS stock, worth $328,201. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,705
Previous 55,312
130.88%
Holding current value
$328,201
Previous $278,000
31.29%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ANVS
# of Institutions
53Shares Held
2.08MCall Options Held
88.1KPut Options Held
188K-
Vanguard Group Inc Valley Forge, PA648KShares$1.67 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY166KShares$427,1820.0% of portfolio
-
Ubs Group Ag161KShares$413,4510.0% of portfolio
-
Geode Capital Management, LLC Boston, MA153KShares$392,2150.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$258,8220.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $21M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...